Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

1968 - The difference in prognostic outcomes between de novo stage IV and recurrent metastatic patients with hormone receptor-positive, HER2-negative breast cancer: a single-center study

Date

10 Oct 2016

Session

Poster display

Presenters

Jun Yamamura

Citation

Annals of Oncology (2016) 27 (6): 68-99. 10.1093/annonc/mdw365

Authors

J. Yamamura1, S. Kamigaki2, M. Tsujie3, J. Fujita3, H. Osato3

Author affiliations

  • 1 Surgery, Breast Oncology, Sakai City Medical Center, 593-8304 - Sakai/JP
  • 2 Surgery, Breast Oncology, Sakai City Medical Center, Sakai/JP
  • 3 Surgery, Sakai City Medical Center, 593-8304 - Sakai, Osaka/JP
More

Resources

Abstract 1968

Background

The difference in prognostic outcomes between de novo stage IV and recurrent metastatic breast cancer is still unclear, and these patients have often been treated with the same treatment strategies. The objective of this retrospective single-center study was to compare prognostic outcomes between these patients, in particular patients with hormone receptor-positive (HR+), HER2-negative (HER2-) metastatic breast cancer. This analysis may help us to interpret results from current clinical research and propose future studies.

Methods

This is a chart review study of de novo stage IV and recurrent metastatic patients with HR + /HER2- breast cancer, who were treated between January 2000 and December 2015 in Sakai City Medical Center, Japan. We used the Kaplan-Meier method to estimate overall survival of the two groups. The Cox proportional hazards model was used to examine the prognostic evaluation between the groups by using two prognostic indicators: disease-free interval (DFI) and interval from the end of adjuvant treatment to the first recurrence (AFI).

Results

We studied 145 patients, including 52 de novo stage IV and 93 recurrent metastatic patients with HR + /HER2- breast cancer. There was no significant difference in prognosis between the groups. However recurrent patients with DFI 

Conclusions

De novo stage IV breast cancer had better prognosis due to therapy-naive or less resistant metastatic disease compared with recurrent patients with DFI 

Clinical trial identification

Legal entity responsible for the study

Sakai City Hospital Orgaization

Funding

Sakai City Hospital Orgaization

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings